Modulation of airway inflammation to prevent exacerbations of COPD

European Respiratory Review

Volumn 14, Issue 95, 2005, Pages 78-82

  Soler M ^a  

^a St Claraspital AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Om 85; Pharmacotherapy; prevention

Indexed keywords

BACTERIUM LYSATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; IMMUNOSTIMULATING AGENT; IPRATROPIUM BROMIDE; IRRITANT AGENT; LONG ACTING DRUG; OM 85; PREDNISONE; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MODULATION; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING CESSATION;

EID: 29744448527     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.05.00009507     Document Type: Review

References (28)

1. Royal College of Physicians. NICE-Guideline on chronic obstructive pulmonary disease. Thorax 2004; 95: Suppl. 1, 1-232.
2. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not in ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-364.
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
5. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-1320.
6. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control stoudy. Thorax 2003; 58: 37-42.
7. Garcia-Aymerich J, Monso E, Marrades RM, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation - EFRAM-study. Am J Respir Crit Care Med 2001; 164: 1002-1007.
8. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
9. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
10. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449-456.
11. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
12. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
13. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
14. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ, 320: 1297-1303.
15. Pauwels R, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
16. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819-1823.
17. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
18. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-1947.
19. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-460.
20. Collet JP, Shapiro S, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1719-1724.
21. Orcel B, Delclaux B, Baud M, Derenne Ph. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 1994; 7: 446-452.
22. Solèr M, Mütterlein R, Cozma G. Prevention of acute exacerbations in chronic bronchitis and COPD with OM-85: a double-blind, placebo-controlled trial. ATS International Conference Proceedings 2004, A766.
23. Lusuardi M, Capelli A, Donner CF. Lung immune defences after stimulation of gut-associated lymphoid tissue with OM-85 BV: a double-blind study in patients with chronic bronchitis. Eur Respir Rev 1996; 6: 182-185.
24. Emmerich B, Emslander HP, Fachmann K, et al. Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Bronco-AvxomR, on T-lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 1990; 57: 90-99.
25. Quezada A, Maggi L, Perez MA, Rodriguez J. Effect of bacterial antigen lysate on IgG and IgA levels in children with recurrent infections and hypogammaglobulinaemia. J Inv Allergol Clin Immunol 1999; 9: 178-182.
26. Grove AK, Bergemann R, Keller R. Preventive treatment of chronic bronchitis: a cost-effectiveness analysis for an immunoactive bacterial extract in Switzerland. BMJ Economics 1996; 10: 1-14.
27. Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patient with chronic obstructive pulmon-ary disease. Can Respir J 2001; 8: 27-33.
28. Steurer-Stey C, Bachmann LM, Steurer J, Tramer MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126: 1645-1655.